This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Buy 5 Medical Instruments Stocks to Enhance Your Portfolio
by Nalak Das
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These stocks are: ALC, RXST, HOLX, VCYT, MASI.
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
3 Solid Buys From MedTech Following 2024 Guidance Raise
by Urmimala Biswas
Guidance hikes by BSX, ALGN and ALC for 2024 make them attractive investment bets.
Alcon (ALC) Q1 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
Alcon's (ALC) Q1 results reflect substantial growth in its franchises on the back of healthy markets.
Here's Why You Should Retain Centene (CNC) Stock for Now
by Zacks Equity Research
Centene (CNC) remains well-poised for growth on the back of sound growth in membership, divestitures and a growing cash balance.
Compared to Estimates, Alcon (ALC) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Alcon (ALC) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
2 Intriguing Medical Stocks to Buy for Steady Growth as Earnings Approach
by Shaun Pruitt
Among the medical sector, Alcon (ALC) and Prestige Consumer Healthcare (PBH) are two intriguing stocks to buy for growth as their quarterly results approach on Tuesday, May 14.
Why Alcon (ALC) Might Surprise This Earnings Season
by Zacks Equity Research
Alcon (ALC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Here's How SONY is Placed Just Ahead of Q4 Earnings Release
by Zacks Equity Research
SONY's Q4 revenues are likely to have been affected by lower hardware sales. Strength in the Music and Pictures segments is likely to have provided some cushioning to the top-line performance.
Soft Instrument Orders Likely to Hurt PacBio's (PACB) Q1 Earnings
by Zacks Equity Research
Despite strength in Revio and Onso platforms, an increasing number of customers delaying instrument purchases is likely to have dampened PacBio's (PACB) top line in the first quarter.
ALC vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
ALC vs. EW: Which Stock Is the Better Value Option?
Are Medical Stocks Lagging DaVita (DVA) This Year?
by Zacks Equity Research
Here is how DaVita HealthCare (DVA) and Alcon (ALC) have performed compared to their sector so far this year.
PetIQ (PETQ) Gears Up to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
PetIQ's (PETQ) first-quarter results are likely to reflect growth in the Product and Services segments of the business.
Here's How Cresco Labs (CRLBF) is Placed Before Q1 Earnings
by Zacks Equity Research
Cresco Labs' (CRLBF) rationalization and optimization efforts are expected to have had a positive impact on the company's first-quarter margins, profitability and cash flow.
Should SNDL (SNDL) be in Your Portfolio Ahead of Q1 Earnings?
by Riya Anand
SNDL's (SNDL) first-quarter performance is expected to benefit from reduced cost expenses and expansion into the liquor retail segment.
McKesson (MCK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fourth-quarter fiscal 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
Should You Buy Hims & Hers Health (HIMS) Ahead of Q1 Earnings?
by Urmimala Biswas
Hims & Hers Health's (HIMS) first-quarter earnings are expected to have benefited from its strategy of placing its solutions at attractive price points.
Will Rate Hikes Aid Hartford Financial's (HIG) Q1 Earnings?
by Zubia Masood
Hartford Financial's (HIG) Q1 results are likely to benefit from new business growth and expanding margins in the Commercial Lines unit, partly offset by the poor performance of the auto business.
Here's Why Investors Should Buy Alcon (ALC) Stock Right Now
by Zacks Equity Research
Strength in the Surgical and Vision Care businesses bodes well for Alcon (ALC).
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Analyst Blog Highlights Booking Holdings, Mitsubishi UFJ Financial, Micron Technology, American Electric Power and Alcon
by Zacks Equity Research
Booking Holdings, Mitsubishi UFJ Financial, Micron Technology, American Electric Power and Alcon are part of the Zacks Analyst Blog.
Top Analyst Reports for Booking Holdings, Mitsubishi UFJ & Micron Technology
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Booking Holdings Inc. (BKNG), Mitsubishi UFJ Financial Group, Inc. (MUFG) and Micron Technology, Inc. (MU).
Alcon's (ALC) New Launch Strengthens IOL Innovation Leadership
by Zacks Equity Research
Alcon's (ALC) Clareon platform is available in India in two PCIOL technologies, PanOptix and Vivity.
Alcon's (ALC) Vivity EDOF IOL Achieves One Million Milestone
by Zacks Equity Research
Alcon's (ALC) Vivity features the first-of-its-kind, patented wavefront-shaping technology, which simplifies presbyopia correction for surgeons and patients.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.